- socially bharat
- November 6, 2024
BioStock: Biosergen’s CEO: “I’m optimistic that we may cure patients”
Biosergen recently announced the completion of treatment for the first cohort of patients in its proof-of-concept trial for its antifungal drug
READ MORE
- socially bharat
- October 26, 2024
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints
- socially bharat
- October 5, 2024
STD clinics should be friendly to gender diverse patients: Health Ministry SOP states
Previously, a white paper released by the Health Ministry indicated that there is a need to re-evaluate documents defining the “Indian standard of care”. File.
- socially bharat
- September 30, 2024
Amoebic encephalitis: Doctors directed to check cerebrospinal fluid samples of all patients suspected to be having meningitis
With more cases of amoebic meningoencephalitis surfacing in the State, the Health department has given the directive to all clinicians that cerebrospinal fluid samples of
- socially bharat
- September 29, 2024
Environmental Factor – September 2020: Severely ill COVID-19 patients may benefit from glucocorticoid drug
In the search for effective COVID-19 treatments, a ray of hope has appeared. A synthetic glucocorticoid called dexamethasone, used for decades to treat conditions ranging
- socially bharat
- September 25, 2024
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/ß-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
TOKYO, Japan & MALVERN, Pa., United States: —Expected to Be First Commercially-Available Blood-Based In-Vitro Diagnostic for Patients Being Assessed for
- socially bharat
- September 14, 2024
Bengaluru hospital to provide free surgical treatment for BPL epilepsy patients
To reduce the burden of epilepsy in economically disadvantaged communities, a city-based private hospital on Saturday launched an Epilepsy Prevention and Integrated Care (EPIC) programme.
- socially bharat
- September 13, 2024
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in
- socially bharat
- September 12, 2024
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients
Baar, Switzerland: CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by